Adaptive immune response in women from the Russian Arctic region after COVID-19 infection
- Authors: Shashkova E.Y.1, Shchegoleva L.S.1, Filippova O.E.1, Popovskaya E.V.1, Sergeeva T.B.1
-
Affiliations:
- N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
- Issue: Vol 30, No 11 (2023)
- Pages: 857-863
- Section: ORIGINAL STUDY ARTICLES
- URL: https://journals.rcsi.science/1728-0869/article/view/257881
- DOI: https://doi.org/10.17816/humeco624207
- ID: 257881
Cite item
Full Text
Abstract
BACKGROUND: The Arctic region of Russia is characterized by disproportionately high rates of morbidity and mortality from COVID-19 during the pandemic. The harsh climatic and environmental conditions in this area impede the development of self-regulation processes resulting in activation and strain of both cellular and humoral immunity. This leads to a depletion of the body’s reserve capacities. At present, there is lack of research examining how individuals who have recovered from COVID-19 are affected by the extreme conditions of Arctic Russia.
AIM: To study the ratio of immunocompetent cells involved in the adaptive immune response following COVID-19 infection.
MATERIAL AND METHODS: A total of 29 women aged 20 – 40 years were examined in Arkhangelsk as part of a comprehensive immunological study. This study involved assessment of the number of leukocytes, lymphocytes, and their phenotypes (CD5+, CD8+, CD10+, CD95+), as well as determination of phagocytic activity and phagocytic number.
RESULTS: The cellular adaptive immune response in observed individuals 6 months after experiencing moderate COVID-19 disease was characterized by a very low concentration of T cells (CD5+) in all cases, CD10+ lymphocytes (44.83%) alongside with a high concentration of cytotoxic lymphocytes (CD8+) in 48.27% of individuals and lymphocytes with receptors for apoptosis (CD95+) in 51.72%, with relatively high phagocytic activity ranging from 90 to 100%. A correlation was found in 11.29% of women between the low content of CD10+ and CD95+ cells with the activity of phagocytosis. In 40% of women with high phagocytic activity, the concentrations of cytotoxic cells (CD8+) were found to be at a minimum level.
CONCLUSIONS: Women with high phagocytic activity were found to have the lowest concentrations of cytotoxic cells, suggesting a potentially positive prognosis for reducing the risk of complications. This indicates that cellular immunity may play a role in determining the severity of COVID-19 infection in individuals with high phagocytic activity.
Full Text
##article.viewOnOriginalSite##About the authors
E. Y. Shashkova
N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
Author for correspondence.
Email: eli1255@ya.ru
ORCID iD: 0000-0002-1735-6690
SPIN-code: 8137-0571
Cand. Sci. (Biology)
Russian Federation, 249 Lomonosov ave., Arkhangelsk, 163000L. S. Shchegoleva
N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
Email: shchegoleva60@mail.ru
ORCID iD: 0000-0003-4900-4021
SPIN-code: 6859-2123
Dr. Sci. (Biology), Professor
Russian Federation, ArkhangelskO. E. Filippova
N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
Email: eli1255@ya.ru
ORCID iD: 0000-0001-6117-0562
SPIN-code: 8507-7525
Cand. Sci. (Biology)
Russian Federation, ArkhangelskE. V. Popovskaya
N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
Email: miakati15@gmail.com
ORCID iD: 0000-0002-6306-1068
SPIN-code: 4890-4668
Russian Federation, Arkhangelsk
T. B. Sergeeva
N. Laverov Federal Center for Integrated Arctic Research of the Ural Branch of the Russian Academy of Science
Email: tanya--86@mail.ru
ORCID iD: 0000-0003-0745-3099
SPIN-code: 6139-1758
Cand. Sci. (Biology)
Russian Federation, ArkhangelskReferences
- Hathaway ED. American Indian and Alaska native people: Social vulnerability and COVID-19. The Journal of Rural Health. 2021;37(1):256–259. doi: 10.1111/jrh.12505
- Donaldson S, Adlard B, Odland JØ. Overview of human health in the Arctic: conclusions and recommendations. International Journal of Circumpolar Health. 2016;75:33807. doi: 10.3402/ijch.v75.33807
- Akimkin VG, Popova AY, Ploskireva АА, et al. COVID-19: the evolution of the pandemic in Russia. Report I: manifestations of the COVID-19 epidemic process. Journal of Microbiology, Epidemiology and Immunobiology. 2022;99(3):269–286. EDN: ZXGTFD doi: 10.36233/0372-9311-276
- Troshina EA, Melnichenko GA, Senyushkina ES, Mokryshe- va NG. Adaptation of the hypothalamo-pituitary-thyroid and hypothalamo-pituitary-adrenal systems to a new infectious disease — COVID-19 in the development of COVID-19 pneumonia and/or cytokine storm. Clinical and Experimental Thyroidology. 2020;16(1):21–27. EDN: ISXSTK doi: 10.14341/ket12461
- Kaufmann SH, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery. 2018;17(1):35–56. doi: 10.1038/nrd.2017.162
- Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology. 2020;38(1):10–18. doi: 10.12932/AP-200220-0773
- Knyazev S, Chhugani K, Sarwal V, et al. Unlocking capacities of genomics for the COVID-19 response and future pandemics. Nature Methods. 2022;19(4):374–380. doi: 10.1038/s41592-022-01444-z
- Van Damme W, Dahake R, Delamou A, et al. The COVID-19 pandemic: diverse contexts; different epidemics — how and why? BMJ Global Health. 2020;5(7):e003098. doi: 10.1136/bmjgh-2020-003098
- Smirnov VS, Totolyan AA. Innate immunity during coronavirus infection. Russian Journal of Infection and Immunity. 2020;10(2): 259–268. EDN: WZIDLN doi: 10.15789/2220-7619-III-1440
- Toptygina AP, Semikina EL, Zakirov RSh, Afridonova ZE. Comparison of the humoral and cellular immunity in COVID-19 convalescents. Russian Journal of Infection and Immunity. 2022;12(3):495–504. EDN: UJQPUV doi: 10.15789/2220-7619-COT-1809
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063
- Stephens DS, McElrath MJ. COVID-19 and the path to immunity. Jama. 2020;324(13):1279–1281. doi: 10.1001/jama.2020.16656
- Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501. doi: 10.1016/j.cell.2020.05.015
- Alotaibi F, Rytelewski M, Figueredo R, et al. CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity. European Journal of Immunology. 2020;50(5):695–704. doi: 10.1002/eji.201948309
- Freitas CMT, Johnson DK, Weber KS. T cell calcium signaling regulation by the co-receptor CD5. International Journal of Molecular Sciences. 2018;19(5):1295. doi: 10.3390/ijms19051295